Examkin

Question

Difficulty: HardGynecologic Infections

During a routine evaluation at a women's health clinic, a 31-year-old G2P2 reports a 4-day history of worsening lower pelvic discomfort, deep dyspareunia, and intermittent vaginal spotting. Her last menstrual period occurred 2 weeks ago. She mentions becoming sexually active with a new partner two months ago. Her medical history is significant for the insertion of a copper intrauterine device three years ago. Her temperature is 38.2°C (100.8°F), blood pressure is 110/70 mmHg, and pulse is 88/min. Speculum examination reveals a yellow, mucopurulent discharge at the cervical os along with visible intrauterine device strings. Bimanual examination elicits significant cervical motion tenderness as well as bilateral adnexal fullness and guarding. A urine pregnancy test is negative. Which of the following is the most appropriate next step in the management of this patient?

  1. Administer intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; leave the intrauterine device in placeAnswer
  2. B
    Remove the intrauterine device, then administer intramuscular ceftriaxone, oral doxycycline, and oral metronidazole
  3. C
    Admit the patient for intravenous cefoxitin and oral doxycycline; leave the intrauterine device in place
  4. D
    Administer intramuscular ceftriaxone and a single dose of oral azithromycin; leave the intrauterine device in place
  5. E
    Administer oral ciprofloxacin and oral metronidazole; leave the intrauterine device in place

Answer

Administer intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; leave the intrauterine device in place
The correct approach is to administer intramuscular ceftriaxone, oral doxycycline, and oral metronidazole while leaving the intrauterine device in place. This patient meets the clinical criteria for mild-to-moderate pelvic inflammatory disease (PID). Because she is hemodynamically stable, not pregnant, and lacks signs of severe systemic illness or a tubo-ovarian abscess, outpatient management is appropriate. The Centers for Disease Control and Prevention (CDC) recommends a single intramuscular dose of ceftriaxone along with 14 days of oral doxycycline and oral metronidazole to provide comprehensive coverage against Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobic organisms. Furthermore, current guidelines recommend leaving the intrauterine device in place during initial therapy; it should only be removed if the patient fails to show clinical improvement after 48 to 72 hours of targeted treatment.

Step-by-Step Solution

1
Identify the clinical syndrome based on the presentation.
The patient has pelvic pain, fever, mucopurulent cervicitis, and cervical motion tenderness, which establishes a clinical diagnosis of acute pelvic inflammatory disease (PID).
Recognizing the diagnostic criteria for PID is the first step before determining the setting of care and pharmacotherapy.
2
Determine the appropriate setting of care (inpatient vs. outpatient).
The patient is hemodynamically stable, tolerating oral intake, not pregnant, and lacks signs of a surgical emergency or severe systemic toxicity.
Mild-to-moderate PID can be safely managed in an outpatient setting, avoiding unnecessary hospitalization and intravenous antibiotics.
3
Select the guideline-concordant empiric antibiotic regimen.
Outpatient treatment requires coverage for N. gonorrhoeae, C. trachomatis, and anaerobes using a single dose of IM ceftriaxone plus 14 days of oral doxycycline and oral metronidazole.
Polymicrobial coverage is essential to prevent long-term sequelae such as infertility and chronic pelvic pain.
4
Address the presence of the copper intrauterine device (IUD).
The IUD should be left in place while initiating empiric antibiotics.
Evidence shows that early removal of an IUD does not improve clinical outcomes in acute PID. Removal is only indicated if there is no clinical improvement after 48-72 hours of appropriate antibiotic therapy.

Key Concept

Management of mild-to-moderate pelvic inflammatory disease in patients with an intrauterine device
Rate this question

Topics

Gynecologic Infections

More questions from this topic